Beijing Med Pharm To Exclusively Market Novartis’ Enablex In China
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - Beijing Med-Pharm (BMP) entered into an exclusive licensing agreement Nov. 26 with Novartis subsidiary Shanghai Novartis Trading Limited, for its bladder treatment drug Enablex (darifenacin) in China
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).